The central nervous system (CNS), comprised of the brain and spinal cord, is responsible for integrating sensory inputs and coordinating body functions. Dysfunction of the CNS leads to serious and often fatal conditions, such as neurodegenerative diseases, as well as migraine and headache disorders, and chronic pain. These conditions are each associated with diverse and debilitating symptoms, which include severe pain, fatigue, lack of motor coordination/balance, and paralysis. Treatment options for the disorders are limited and new approaches to improve patient outcomes are needed. Therefore, Teva is seeking proposals for novel intracellular or extracellular targets with therapeutic potential to alleviate the conditions of people suffering from neurodegenerative diseases, migraine and headache disorders, and pain.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.
Neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and Parkinson’s disease (PD), are becoming an increasing public health concern as the global population ages. Effective treatment options for these debilitating and fatal conditions are severely limited. Although there has been much progress in recent years unraveling disease mechanisms, the underlying causes of these diseases are not well understood. Even in cases where disease-causing mutations have been identified, it is still unclear how they lead to neuronal death, and ultimately, to the specific cognitive and/or motor deficits associated with each disorder.
Migraine, headache disorders and chronic pain are additional areas of unmet need. An estimated 1.5 billion people globally suffer from chronic pain, and in one in three people the ability to sustain an independent lifestyle is impaired due to pain. Furthermore, about 100 million people in the United States suffer from headaches, of which 37 million have migraines. Migraine sufferers typically suffer from moderate to severe pain limiting their participation in normal activities and impacting their overall quality of life. Effective treatments without deleterious side effects are urgently needed.
The key to discovering effective treatments lies in understanding the basic mechanism or pathophysiology of the condition, thus uncovering new pathways and targets. Successful proposals for this Challenge should focus on novel intracellular or extracellular targets that can be modulated by small molecules or biologics to alleviate the conditions of people suffering from neurodegenerative disorders, including ALS, HD and PD, as well as migraine, headache disorders, or pain.
This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a proposal (maximum of 10 pages, not including references and contact details) to be evaluated by Teva.
The ALS Association and the Huntington’s Disease Society of America (HDSA) are partnering with Teva and co-sponsoring the Challenge awards to seek novel targets with therapeutic potential for ALS and HD, respectively.
The top submissions will be considered for awards ranging from $10,000 to $30,000. Up to $40,000 in cash awards may be distributed. Solvers are NOT eligible for multiple awards. The award has no strings attached; Teva does not request ownership of intellectual property. In addition, if there is mutual interest of the parties, Teva may invite selected Solvers to work out terms for a collaboration contract to further investigate the target. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame.
[NOTE: Proposals from Solvers who have the ability to work as a collaboration partner are not required, but are highly encouraged.]
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on April 29, 2018.
Late submissions will not be considered.
ABOUT THE SEEKER
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.
ABOUT THE PARTNER FOUNDATIONS
About The ALS Association
The ALS Association is the only national non-profit organization fighting Lou Gehrig’s Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure. For more information about The ALS Association, visit our website at www.alsa.org.
About the Huntington’s Disease Society of America (HDSA)
The Huntington’s Disease Society of America (HDSA) is the premier nonprofit organization dedicated to improving the lives of everyone affected by Huntington’s disease. From community services and education to advocacy and research, HDSA is the world’s leader in providing help for today and hope for tomorrow for people with Huntington’s disease and their families. To learn more about Huntington’s disease and the work of the Huntington’s Disease Society of America, visit www.hdsa.org or call 1-800-345-HDSA.
What is an eRFP Challenge?
eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.
After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.
This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.